Literature DB >> 15041507

Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis.

Ken Shirabe1, Mitsuo Shimada, Eiji Tsujita, Shin-ichi Aishima, Shin-ichiroh Maehara, Sinji Tanaka, Kenji Takenaka, Yoshihiko Maehara.   

Abstract

BACKGROUND: The aim of this study was to clarify prognostic factors and recurrence patterns in patients with node-negative intrahepatic cholangiocarcinoma (IHCC).
METHODS: A retrospective study was performed to review prognostic factors and recurrence patterns (1) in 22 patients with node-negative IHCC after curative hepatic resection and (2) in 49 patients who underwent resection and lymph node dissection for IHCC. In addition to determining the clinicopathologic factors, the investigators also performed immunohistochemical examination of microvessel counts using antihuman CD-31 and antibody.
RESULTS: The significant poor prognostic factors in node-negative IHCC were the presence of intrahepatic metastasis, portal vein invasion of cancer cells, and high microvessel counts. After multivariate analysis was conducted, the independent poor prognostic factors were the presence of intrahepatic metastases and high microvessel counts. Of 9 patients who had postoperative recurrence of their disease, intrahepatic recurrence was observed in 7 (78 %).
CONCLUSIONS: The factors linked to poor prognosis in IHCC were tumor angiogenesis and the presence of intrahepatic metastasis. Because intrahepatic recurrence was common, regional and adjuvant chemotherapy to the liver may improve the outcome of patients with these risk factors and node-negative IHCC.

Entities:  

Mesh:

Year:  2004        PMID: 15041507     DOI: 10.1016/j.amjsurg.2003.12.044

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  16 in total

1.  Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis.

Authors:  Sarah B Fisher; Sameer H Patel; David A Kooby; Sharon Weber; Mark Bloomston; Clifford Cho; Ioannis Hatzaras; Carl Schmidt; Emily Winslow; Charles A Staley; Shishir K Maithel
Journal:  HPB (Oxford)       Date:  2012-05-22       Impact factor: 3.647

2.  Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

Authors:  Chantal Dreyer; Marie-Paule Sablin; Mohamed Bouattour; Cindy Neuzillet; Maxime Ronot; Safi Dokmak; Jacques Belghiti; Nathalie Guedj; Valérie Paradis; Eric Raymond; Sandrine Faivre
Journal:  World J Hepatol       Date:  2015-04-28

3.  Cyclooxygenase-2 expression determines neo-angiogenesis in gallbladder carcinomas.

Authors:  Mateja Legan; Bostjan Luzar; Vera Ferlan-Marolt; Andrej Cör
Journal:  Bosn J Basic Med Sci       Date:  2006-11       Impact factor: 3.363

4.  Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors.

Authors:  Shigeru Marubashi; Kunihito Gotoh; Hidenori Takahashi; Hiroaki Ohigashi; Masahiko Yano; Osamu Ishikawa; Masato Sakon
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

5.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

Review 6.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

7.  A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium.

Authors:  Cecilia G Ethun; Lauren M Postlewait; Nina Le; Timothy M Pawlik; Stefan Buettner; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Nipun Merchant; Kenneth Cardona; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2016-11-03       Impact factor: 5.344

8.  CD24 expression is an independent prognostic marker in cholangiocarcinoma.

Authors:  Shefali Agrawal; Boris W Kuvshinoff; Thaer Khoury; Jihnhee Yu; Milind M Javle; Charles LeVea; Jeff Groth; Lionel J Coignet; John F Gibbs
Journal:  J Gastrointest Surg       Date:  2007-04       Impact factor: 3.452

9.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 10.  The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.

Authors:  Silvia Affo; Le-Xing Yu; Robert F Schwabe
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.